Clinical trials: PSA Progression, active
PCA, Prostate Cancer
PSMA PET Combined With MRI for the Detection of PCa
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection…
- Conditions
- PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET
- Trial name
- BiPASS (NCT07052214)
- Testing
- 68Ga-PSMA-11
- Where
- 18 sites in United States, Australia
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
PSA Progression, PSA
MRI-Assisted Guidance for Non-Essential Tissue Sampling
The study aims to determine if a less painful and less invasive prostate biopsy approach is safe for certain men with a high risk of prostate cancer.
- Trial name
- NCT07516223
- Testing
- Paired Prostate Biopsy Cohort (TB + SB)
- Where
- China
- Volunteers
- 1,235 people
- Sponsor
- Shanghai East Hospital
Prostate Cancer (Post Prostatectomy)
PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer.
- Trial name
- NCT06617481
- Testing
- 18F-rhPSMA-7.3 (Posluma)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- AdventHealth
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
This phase II trial studies how well finite androgen ablation with or without abiraterone acetate and prednisone work in treating patients with prostate cancer that has come back.
- Trial name
- NCT01786265
- Testing
- Abiraterone Acetate, Bicalutamide, Degarelix
- Where
- United States
- Volunteers
- 310 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA
This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance.
- Trial name
- NCT06600698
- Testing
- INM176
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Milton S. Hershey Medical Center
Health Status Unknown, Elevated PSA
Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA
This randomized phase II trial studies how well systematic random biopsy or magnetic resonance imaging (MRI)-ultrasound image (US) fusion biopsy work in diagnosing prostate cancer in patients with elevated prostate specific…
- Trial name
- NCT03234556
- Testing
- Biopsy of Prostate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging
- Where
- 4 sites in United States
- Volunteers
- 288 people
- Sponsor
- University of Southern California
Prostate Cancer, Elevated PSA
Upright MRI for Prostate Cancer Screening
This is an investigator initiated study to test the efficacy of an upright MRI (Magnetic Resonance Imaging) for the screening of prostate cancer.
- Conditions
- Prostate Cancer, Elevated PSA, Elevated Prostate Specific Antigen
- Trial name
- NCT03474913
- Testing
- Upright MRI, Standard MRI
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Metastatic Castration-Resistant Prostate Cancer, mCRPC
REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants
This study will test an experimental Regeneron drug called REGN21353 ("study drug") to see if it can help treat previously treated prostate cancer that has spread (also called metastatic castration-resistant prostate cancer or…
- Trial name
- NCT07850921
- Testing
- REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency)
- Volunteers
- 192 people
- Sponsor
- Regeneron Pharmaceuticals
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received…
- Trial name
- EvoPAR-PR05 (NCT07711002)
- Testing
- Saruparib, Enzalutamide, Darolutamide
- Where
- 210 sites in United States, Austria and 19 more
- Volunteers
- 1,330 people
- Sponsor
- AstraZeneca
Prostate Cancer
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
Background: Active surveillance (AS) is a standard approach to treat low and intermediate risk prostate cancer. For AS, disease progression is monitored.
- Trial name
- NCT04692675
- Testing
- mpMRI
- Where
- United States
- Volunteers
- 508 people
- Sponsor
- National Cancer Institute (NCI)
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
This randomized phase II trial studies the side effects and how well abiraterone acetate, prednisone, and apalutamide work with or without ipilimumab or cabazitaxel and carboplatin in treating patients with castration-resistant…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression
- Trial name
- NCT02703623
- Testing
- Abiraterone Acetate, Apalutamide, Cabazitaxel
- Where
- 3 sites in United States
- Volunteers
- 196 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Molecular Studies and Clinical Correlations in Human Prostatic Disease
The Genitourinary Oncology/Urology Services at Memorial Sloan-Kettering Cancer Center (MSKCC) participates in research for the control, treatment, and cure of cancer.
- Trial name
- NCT00578240
- Where
- United States
- Volunteers
- 5,290 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer, Metastatic Prostate Cancer
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
This study is designed to test the hypothesis that using Sipuleucel-T (Provenge) in combination with new hormonal agents (NHA) (abiraterone, enzalutamide, apalutamide) for the treatment of participants with asymptomatic…
- Trial name
- NCT05751941
- Testing
- Abiraterone, Enzalutamide, Apalutamide
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
PSA Level Greater Than 0.03, PSA Progression
Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery
This phase II trial studies how well stereotactic body radiation therapy works in treating patients with prostate cancer that has not spread to other parts of the body and have undergone surgery.
- Conditions
- PSA Level Greater Than 0.03, PSA Progression, Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) v7, Stage II Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT03541850
- Testing
- Antiandrogen Therapy, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Prostate Cancer
Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer
The purpose of this clinical trial is to determine the anti-tumor activity of talazoparib plus enzalutamide as first line treatment for metastatic castration resistant prostate cancer (mCRPC) in participants whose disease has…
- Trial name
- TEAM PC (NCT06582628)
- Testing
- Enzalutamide capsule, Enzalutamide capsule and Talazoparib capsule
- Where
- 19 sites in France, Spain
- Volunteers
- 78 people
- Sponsor
- Fundacion Oncosur
Inflammatory Joint Diseases, Rheumatoid Arthritis (RA)
Oxidative Stress in Autoimmune Rheumatic Diseases
Rheumatic diseases constitute a group of non-communicable diseases characterized by chronic inflammation. The most common autoimmune rheumatic diseases (ARDs) are rheumatoid arthritis, psoriatic arthritis, systemic lupus…
- Conditions
- Inflammatory Joint Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS)
- Trial name
- REDOX-ARD (NCT07536529)
- Where
- Greece
- Volunteers
- 200 people
- Sponsor
- University of Thessaly
Metastatic Castration-resistant Prostate Cancer
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor…
- Trial name
- NCT06520345
- Testing
- 177Lu-TLX591, Enzalutamide, Abiraterone
- Where
- 33 sites in United States, Australia and 4 more
- Volunteers
- 520 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
This is a phase II, single-center, open-label, trial to evaluate the diagnostic accuracy of PSMA-targeted 18F-DCFPyL PET/CT for detecting clinically significant prostate cancer in a screening population.
- Trial name
- NCT03471650
- Testing
- 18F-DCFPyL Injection
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Prostate Risk Or Radiology Assessment Non-inferiority Design, Upfront MRI or Risk Calculator in Men With Suspected Prostate Cancer
Thousands of men take a PSA test to investigate whether they have prostate cancer every year. For the vast majority, the test is normal and further investigations are not necessary.
- Trial name
- PRORAND (NCT07422597)
- Testing
- European Study of screening for prostate cancer risk calculator
- Where
- 3 sites in Norway
- Volunteers
- 1,016 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Suspected Prostate Cancer (increased PSA Level)
Oncological Prognosis of Prostate Lesions by Chemical Exchange Saturation Transfer Magnetic Resonance Imaging (CEST-MRI)
Prostate cancer is the second most common type of cancer in men only after lung cancer, and accounts for ~3.8% of all deaths caused in men in 2018.
- Trial name
- ProstaCEST (NCT06669273)
- Testing
- CEST MRI sequence at 3T
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Clermont-Ferrand